- Target Boycott Shouldn't Worry Investors: It Won't Hurt Sales; Target Responds
- Sarepta Can Win Speedy FDA Drug Approval
- 10 Fuel-Efficient Cars For Your Volkswagen Diesel Buyback Money
- Retirees Are Opting to Rent Homes Likes Millennials
- 10 Countries Where That Social Security Check Will Let You Retire in Style
Thursday's parade of deals seem to answer a question that's been bugging health care investors for most of 2016: why haven't retreating biotech valuations sparked an uptick in M&A activity?
Jim Cramer expects to see more deal activity in the pharmaceuticals space.
Jim Cramer believes the pharmaceutical sector has come full circle and some of the best stocks in the group are ready to move higher.
Senior FDA officials, most notably Dr. Janet Woodcock, the agency's top drug evaluator, spent a lot of time at Monday's panel making supportive statements about eteplirsen.
Facebook is doing everything right it seems.
Vertex Pharmaceuticals tried to soothe fears about the commercial ramp of its cystic fibrosis franchise by providing Orkambi sales guidance for the first time since the drug launched last summer.
MannKind is drowning in debt and fixed purchasing contracts but the company generates no revenue.
New products such as Trulicity, Cyramza, Jardiance, Basaglar and Portrazza fueled the drugmaker's revenue growth in the first quarter.
Is Perrigo about to turn the corner or is the stock doomed? Let's take a look at whether the stock is a value play or ... a value trap.
U.S. stocks lose earlier highs on Tuesday as the health care sector pulls the markets lower.
This big drug maker has released strong first-quarter results, but the stock remains a bitter pill for investors.
Earnings season is upon us, but instead of focusing on short-term data, zero in what really matters and buy these rock-solid dividend stocks for the long run.
Eli Lilly earnings came in short by 2 cents but revenue was slightly higher than estimates.
A weak cold season drives down consumer health revenue in the U.S.
Jim Cramer says investors should own Allergan because the stock is undervalued.
Check Out Our Best Services for Investors
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.